CY1108360T1 - Φαρμακο που περιεχει εναν πολυ ισχυρο, βητα-2-ανταγωνιστη μακρας διαρκειας σε συνδυασμο με αλλα δραστικα συστατικα - Google Patents

Φαρμακο που περιεχει εναν πολυ ισχυρο, βητα-2-ανταγωνιστη μακρας διαρκειας σε συνδυασμο με αλλα δραστικα συστατικα

Info

Publication number
CY1108360T1
CY1108360T1 CY20081101023T CY081101023T CY1108360T1 CY 1108360 T1 CY1108360 T1 CY 1108360T1 CY 20081101023 T CY20081101023 T CY 20081101023T CY 081101023 T CY081101023 T CY 081101023T CY 1108360 T1 CY1108360 T1 CY 1108360T1
Authority
CY
Cyprus
Prior art keywords
active ingredients
powerful
beta
component long
medicinal containing
Prior art date
Application number
CY20081101023T
Other languages
English (en)
Inventor
Roberta Razzetti
Fiorella Pastore
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108360(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of CY1108360T1 publication Critical patent/CY1108360T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη χρήση ενός βρογχοδιασταλτικού σε συνδυασμό με ένα ή περισσότερα επιπλέον δραστικά συστατικά, για την αντιμετώπιση των αναπνευστικών διαταραχών και ιδιαίτερα του άσθματος και της χρόνιας αποφρακτικής πνευμονικής νόσου (COPD) και φαρμακευτικές συνθέσεις που περιέχουν τα αναφερθέντα δραστικά συστατικά. Πιο συγκεκριμένα, η εφεύρεση αφορά τη χρήση του β2-ανταγωνιστή παρατεταμένης δράσης, της 8-υδροξυ-5-[(1R)-1-υδροξυ-2-[[1R)-2-(4-μεθοξυφαινυλ)-1-μεθυλαιθυλ] αμινο] αιθυλ-2 (ΙΗ)-κινολινόλης, και/ ή των φυσιολογικά αποδεκτών αλάτων και/ ή διαλυτών αυτών ως ένα βρογχοδιασταλτικό σε συνδυασμό με άλλα δραστικά συστατικά.
CY20081101023T 2003-02-27 2008-09-19 Φαρμακο που περιεχει εναν πολυ ισχυρο, βητα-2-ανταγωνιστη μακρας διαρκειας σε συνδυασμο με αλλα δραστικα συστατικα CY1108360T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004184A EP1452179A1 (en) 2003-02-27 2003-02-27 Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
EP04715295A EP1603565B1 (en) 2003-02-27 2004-02-27 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

Publications (1)

Publication Number Publication Date
CY1108360T1 true CY1108360T1 (el) 2014-02-12

Family

ID=32748803

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101023T CY1108360T1 (el) 2003-02-27 2008-09-19 Φαρμακο που περιεχει εναν πολυ ισχυρο, βητα-2-ανταγωνιστη μακρας διαρκειας σε συνδυασμο με αλλα δραστικα συστατικα

Country Status (32)

Country Link
US (1) US20070020190A1 (el)
EP (3) EP1452179A1 (el)
JP (1) JP2006519204A (el)
KR (1) KR20050104367A (el)
CN (2) CN100370986C (el)
AR (1) AR043419A1 (el)
AT (1) ATE401887T1 (el)
AU (1) AU2004216472B2 (el)
BR (1) BRPI0408047A (el)
CA (1) CA2517321A1 (el)
CY (1) CY1108360T1 (el)
DE (1) DE602004015260D1 (el)
DK (1) DK1603565T3 (el)
EA (1) EA008828B1 (el)
ES (1) ES2309503T3 (el)
HK (1) HK1087009A1 (el)
HR (1) HRP20050726A2 (el)
MA (1) MA27630A1 (el)
ME (1) MEP32208A (el)
MX (1) MXPA05009007A (el)
NO (1) NO20053959L (el)
NZ (1) NZ541997A (el)
PE (1) PE20050290A1 (el)
PL (1) PL377814A1 (el)
PT (1) PT1603565E (el)
RS (1) RS20050615A (el)
SA (1) SA04250122B1 (el)
SI (1) SI1603565T1 (el)
TN (1) TNSN05186A1 (el)
UA (1) UA82217C2 (el)
WO (1) WO2004075896A1 (el)
ZA (1) ZA200506820B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EP1651224B1 (en) * 2003-07-31 2011-10-05 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising an anticholinergic and a betamimetic
JP2007501194A (ja) * 2003-08-05 2007-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ステロイドとβ模倣薬を含む吸入用薬剤
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
WO2006105401A2 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
EP1915129B1 (en) * 2005-08-01 2009-10-28 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
PL2098248T3 (pl) * 2005-12-21 2012-11-30 Meda Pharma Gmbh & Co Kg Kombinacja antycholinergików, glukokortykoidów i beta2-agonistów do leczenia chorób zapalnych
EP2029127A1 (en) * 2006-05-24 2009-03-04 Boehringer Ingelheim International GmbH New long-acting drug combinations for the treatment of respiratory diseases
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2327403A3 (en) * 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
EP2230934B8 (en) 2007-12-14 2012-10-24 AeroDesigns, Inc Delivering aerosolizable food products
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2309858A4 (en) * 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
AU2010252354B2 (en) * 2009-05-25 2016-05-19 Chiesi Farmaceutici S.P.A. A therapeutic combination comprising a pulmonary surfactant and a steroid
DK2435024T3 (en) 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for the respiratory delivery of active agents and related methods and systems
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
WO2011136753A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
CN110237260A (zh) * 2010-07-16 2019-09-17 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
WO2012010854A1 (en) 2010-07-23 2012-01-26 Cipla Limited Inhalation formulations comprising carmoterol in combination with a corticosteroid
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
HUE038899T2 (hu) * 2013-03-15 2018-12-28 Verona Pharma Plc Gyógyszer kombináció
US10117891B2 (en) 2014-09-16 2018-11-06 India Globalization Capital, Inc. Cannabinoid composition for treating pain
EP3223807B1 (en) 2014-11-24 2021-09-15 The Board of Trustees of the University of Illinois Method of preventing or treating a pulmonary disease or condition
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2017027651A1 (en) * 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
CN115337311B (zh) * 2022-09-26 2023-05-09 南京恒道医药科技股份有限公司 一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
EP0969816B1 (en) * 1997-03-20 2004-12-15 Schering Corporation Preparation of powder agglomerates
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DZ3358A1 (fr) * 2000-05-22 2001-11-29 Chiesi Farma Spa Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
HUE044926T2 (hu) * 2002-03-01 2019-11-28 Chiesi Farm Spa Szuperfinom formoterolkészítmény
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
CN100370986C (zh) 2008-02-27
EP1834643A3 (en) 2007-10-24
BRPI0408047A (pt) 2006-02-14
MXPA05009007A (es) 2005-10-18
CN1753678A (zh) 2006-03-29
SA04250122B1 (ar) 2009-03-11
HRP20050726A2 (en) 2006-02-28
PE20050290A1 (es) 2005-05-26
SI1603565T1 (sl) 2008-10-31
NO20053959D0 (no) 2005-08-25
HK1087009A1 (en) 2006-10-06
ZA200506820B (en) 2006-11-29
US20070020190A1 (en) 2007-01-25
AU2004216472A1 (en) 2004-09-10
PT1603565E (pt) 2008-10-06
EP1834643A2 (en) 2007-09-19
EA008828B1 (ru) 2007-08-31
PL377814A1 (pl) 2006-02-20
DK1603565T3 (da) 2008-11-10
AU2004216472B2 (en) 2009-08-06
NZ541997A (en) 2008-12-24
ES2309503T3 (es) 2008-12-16
ATE401887T1 (de) 2008-08-15
EP1452179A1 (en) 2004-09-01
WO2004075896A1 (en) 2004-09-10
NO20053959L (no) 2005-11-28
UA82217C2 (uk) 2008-03-25
JP2006519204A (ja) 2006-08-24
MA27630A1 (fr) 2005-11-01
CN101244063A (zh) 2008-08-20
DE602004015260D1 (de) 2008-09-04
EA200501108A1 (ru) 2006-04-28
CA2517321A1 (en) 2004-09-10
EP1603565B1 (en) 2008-07-23
KR20050104367A (ko) 2005-11-02
EP1603565A1 (en) 2005-12-14
MEP32208A (en) 2010-10-10
RS20050615A (en) 2007-09-21
AR043419A1 (es) 2005-07-27
TNSN05186A1 (en) 2007-06-11

Similar Documents

Publication Publication Date Title
CY1108360T1 (el) Φαρμακο που περιεχει εναν πολυ ισχυρο, βητα-2-ανταγωνιστη μακρας διαρκειας σε συνδυασμο με αλλα δραστικα συστατικα
CY1119216T1 (el) Φαρμακευτικη συνθεση για εισπνοη
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
PT1326595E (pt) Composicao farmaceutica compreendendo resveratrol para o tratamento de disturbios respiratorios inflamatorios
MX2007012700A (es) Compuestos organicos.
NO20061254L (no) Farmasoytiske blandinger
RU2006132036A (ru) Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
CY1105648T1 (el) Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης
MX2019006938A (es) Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
ECSP066545A (es) Procedimiento para la preparación de sales de tiotropio, sales de tiotropio, así como formulaciones medicamentosas que las contienen
EA200501105A1 (ru) Фармацевтическая композиция
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
EA200500328A1 (ru) Композиция и лекарственное средство для лечения респираторных заболеваний, аллергических заболеваний, астмы и/или хронических обструктивных заболеваний легких и способ получения лекарственного средства
HUP0400222A2 (hu) PDE-4 inhibitort és H1 receptor antagonistát tartalmazó kombináció és ennek alkalmazása tüdőbetegségek kezelésére alkalmas gyógyszerkészítmény előállítására
UY28590A1 (es) Procedimiento para la preparación de nuevas sales de tiotropio, nuevas sales de tiotropio como tales, así como las formulaciones medicamentosas que las contienen.
CY1108323T1 (el) 8-υδροξυ-5-[(1ρ)-1 υδροξυ-2[[(1ρ)-2-(4-μεθοξυφαινυλ)-1-μεθυλαιθυλ] αμινο] αιθυλ]-2(1η)-κινολινονη μονοϋδροχλωριδιο σε κρυσταλλικη μορφη και η διαδικασια για την προετοιμασια του
IS7899A (is) Samverkandi samsetning sem felur í sér róflúmílast og (R.R)-formóteról
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
EA200500864A1 (ru) Новый, содержащий тиотропий порошковый препарат для ингаляции
ATE475409T1 (de) Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten
WO2005011615A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
BR0308984A (pt) Formulações em pó adequadas para inalação
TH77905B (th) ยาชนิดใหม่ซึ่งประกอบรวมด้วย (เบตา)2 -อะโกนิสต์ที่มีการออกฤทธิ์นาน และมีศักยภาพสูงในการใช้ร่วมกับส่วนประกอบออกฤทธิ์อื่นๆ
Sharman European Respiratory Society-26th International Congress. London, UK-September 3-7, 2016